Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Myelofibrosis:

Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge? Salit RB et al. Biol Blood Marrow Transplant. (2018)

Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Marcellino B et al. Clin Adv Hematol Oncol. (2018)

Myelofibrosis: clinicopathologic features, prognosis, and management. O'Sullivan JM et al. Clin Adv Hematol Oncol. (2018)

Search results

Items: 1 to 20 of 8507

1.

Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms.

Katiyar V, Uprety A, Mendez-Hernandez A, Fuentes HE, Andrade XA, Zia M.

TH Open. 2019 Jul 17;3(3):e203-e209. doi: 10.1055/s-0039-1692988. eCollection 2019 Jul.

2.

Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Sankar K, Stein BL, Rampal RK.

Cancer Treat Res. 2019;179:159-178. doi: 10.1007/978-3-030-20315-3_11.

PMID:
31317487
3.

Pathogenesis of aplastic anemia.

Wang L, Liu H.

Hematology. 2019 Dec;24(1):559-566. doi: 10.1080/16078454.2019.1642548.

PMID:
31315542
4.

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO and AMCLI societies.

Girmenia C, Lazzarotto T, Bonifazi F, Patriarca F, Irrera G, Ciceri F, Aversa F, Citterio F, Cillo U, Cozzi E, Gringeri E, Baldanti F, Cavallo R, Clerici P, Barosi G, Grossi P.

Clin Transplant. 2019 Jul 16:e13666. doi: 10.1111/ctr.13666. [Epub ahead of print]

PMID:
31310687
5.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥ 65 years.

Daghia G, Zabelina T, Zeck G, von Pein UM, Christopeit M, Wolschke C, Ayuk F, Kröger N.

Eur J Haematol. 2019 Jul 15. doi: 10.1111/ejh.13294. [Epub ahead of print]

PMID:
31306511
6.

FDG-PET/CT Demonstrates Splenic Angiosarcoma Bone Marrow Metastasis.

Takahashi H, Hara T, Suzuki H, Hashimoto R, Minami M.

Clin Nucl Med. 2019 Jul 12. doi: 10.1097/RLU.0000000000002717. [Epub ahead of print]

PMID:
31306197
7.

Clinical features of precursor-targeted immune-mediated anemia in dogs: 66 cases (2004-2013).

Assenmacher TD, Jutkowitz LA, Koenigshof AM, de A Lucidi C, Scott MA.

J Am Vet Med Assoc. 2019 Aug 1;255(3):366-376. doi: 10.2460/javma.255.3.366.

PMID:
31298643
8.

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH.

Eur J Haematol. 2019 Jul 11. doi: 10.1111/ejh.13292. [Epub ahead of print]

PMID:
31297883
9.

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR.

Haematologica. 2019 Jul 11. pii: haematol.2019.223503. doi: 10.3324/haematol.2019.223503. [Epub ahead of print]

10.

Esophageal Variceal Hemorrhage Secondary to Post-Polycythemic Myelofibrosis.

Motomura D, Kulai T, Epstein I.

J Can Assoc Gastroenterol. 2018 Sep;1(3):95-96. doi: 10.1093/jcag/gwy016. Epub 2018 May 18. No abstract available.

11.

Intestinal Behçet's Disease with Primary Myelofibrosis Involving Trisomy 8.

Narazaki T, Shiratsuchi M, Tsuda M, Tsukamoto Y, Muta H, Masuda T, Kimura D, Takamatsu A, Nakanishi R, Oki E, Fujiwara M, Oda Y, Nakashima Y, Ogawa Y.

Acta Haematol. 2019 Jul 10:1-4. doi: 10.1159/000501019. [Epub ahead of print]

PMID:
31291615
12.

Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis.

Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R 3rd, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N.

Biol Blood Marrow Transplant. 2019 Jul 6. pii: S1083-8791(19)30433-1. doi: 10.1016/j.bbmt.2019.07.001. [Epub ahead of print]

PMID:
31288096
13.

Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Jul 5. pii: S1083-8791(19)30418-5. doi: 10.1016/j.bbmt.2019.06.034. [Epub ahead of print]

PMID:
31284069
14.

[Clinical application of gene mutation information in myeloproliferative neoplasms].

Takenaka K.

Rinsho Ketsueki. 2019;60(6):610-618. doi: 10.11406/rinketsu.60.610. Japanese.

PMID:
31281152
15.

Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.

Ferulli F, Tanzi M, Turin I, Montini E, Rosti V, Acquafredda G, Lisini D, Compagno F, Boghen S, Licari A, Marseglia G, Zecca M, Montagna D.

Cytotherapy. 2019 Jul 4. pii: S1465-3249(19)30790-X. doi: 10.1016/j.jcyt.2019.06.007. [Epub ahead of print]

PMID:
31279696
16.

Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F.

Blood. 2019 Jul 3. pii: blood.2019000051. doi: 10.1182/blood.2019000051. [Epub ahead of print]

PMID:
31270105
17.

Myeloproliferative Neoplasms: A Primer for Radiologists.

Liput J, Smith DA, Beck R, Ramaiya NH.

J Comput Assist Tomogr. 2019 Jul/Aug;43(4):652-663. doi: 10.1097/RCT.0000000000000893.

PMID:
31268881
18.

Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL.

Clin Lymphoma Myeloma Leuk. 2019 May 13. pii: S2152-2650(19)30110-7. doi: 10.1016/j.clml.2019.05.009. [Epub ahead of print]

PMID:
31262666
19.

Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs.

Leiva O, Bekendam RH, Garcia BD, Thompson C, Cantor A, Chitalia V, Ravid K.

TH Open. 2019 Jun 7;3(2):e165-e170. doi: 10.1055/s-0039-1692204. eCollection 2019 Apr. Review.

20.

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.

Marin Oyarzún CP, Heller PG.

Front Immunol. 2019 Jun 14;10:1373. doi: 10.3389/fimmu.2019.01373. eCollection 2019. Review.

Supplemental Content

Loading ...
Support Center